FDA Approves Veozah (fezolinetant) for the Treatment of Vasomotor Symptoms Due to Menopause

TOKYO, May 13 2023– Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura,“Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved Veozah (fezolinetant) 45 mg once daily for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news